Cancer Research UK
- Country
- 🇬🇧United Kingdom
- Ownership
- Private
- Established
- 2002-01-01
- Employees
- 1K
- Market Cap
- -
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
- Conditions
- Bladder CancerCastration-resistant Prostate CancerMelanomaNon-small Cell Lung Cancer (NSCLC)Triple Negative Breast CancerGastric CancerOvarian CancerPancreatic CancerSquamous Cell Cancer of the Head and NeckCervical Cancer
- Interventions
- First Posted Date
- 2021-09-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 81
- Registration Number
- NCT05057013
- Locations
- 🇬🇧
The Christie Hospital, Manchester, United Kingdom
🇬🇧Freeman Hospital, Newcastle, Newcastle, United Kingdom
🇬🇧Royal Marsden NHS Foundation Trust, London, United Kingdom
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1
- Conditions
- Non-small Cell Lung Cancer (NSCLC)Esophageal NeoplasmsNeoplasms, Squamous Cell
- Interventions
- Combination Product: Standard of care treatmentBiological: ChAdOx1-MAGEA3-NYESOBiological: MVA-NYESO
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 15
- Registration Number
- NCT04908111
- Locations
- 🇬🇧
Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom
🇬🇧Blackpool Victoria Hospital, Blackpool, United Kingdom
🇬🇧The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 34
- Registration Number
- NCT04455815
- Locations
- 🇬🇧
The Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
🇬🇧Church Avenue Medical Group, Harrogate, United Kingdom
🇬🇧Clarence Medical Centre, Rhyl, United Kingdom
BT1718 in Patients with Advanced Solid Tumours.
- Conditions
- Non-Small Cell Lung CancerAdvanced Solid TumoursNon-Small Cell Lung SarcomaOesophageal Cancer
- Interventions
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 72
- Registration Number
- NCT03486730
- Locations
- 🇬🇧
Addenbrookes Hospital, Cambridge, United Kingdom
🇬🇧Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom
🇬🇧Queen Elizabeth Hospital, Birmingham, United Kingdom
AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- Biological: AST-VAC2
- First Posted Date
- 2017-12-13
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 9
- Registration Number
- NCT03371485
- Locations
- 🇬🇧
Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧Southampton General Hospital, Southampton, United Kingdom
A CR-UK Phase I Trial of LY3143921
- Conditions
- A. Colorectal CancerB. High Grade Serous Ovarian CancerC. Non Small-cell Lung Cancer (squamous Cell Variant)D. Squamous Carcinoma of the OesophagusE. Squamous Carcinoma of the Head and Neck (HPV Negative)F. Urothelial CancerG. Breast Cancer (triple Negative Type)H. Pancreatic Cancer
- Interventions
- Drug: LY3143921 hydrate
- First Posted Date
- 2017-03-30
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 69
- Registration Number
- NCT03096054
- Locations
- 🇬🇧
Cancer Centre, Belfast City Hospital, Belfast, United Kingdom
🇬🇧Western General Hospital, Edinburgh, United Kingdom
🇬🇧Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
- Conditions
- Chronic Lymphocytic LeukaemiaWaldenström MacroglobulinemiaB-cell Lymphoma
- Interventions
- Biological: BI-1206 single agent dose escalation phaseBiological: BI-1206 single agent expansion phaseBiological: Combination of BI-1206 with rituximab expansion phaseBiological: Combination of BI-1206 with rituximab escalation phase
- First Posted Date
- 2016-10-14
- Last Posted Date
- 2021-07-08
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 14
- Registration Number
- NCT02933320
- Locations
- 🇬🇧
Leicester Royal Infirmary, Leicester, England, United Kingdom
🇬🇧Christie Hospital, Manchester, England, United Kingdom
🇬🇧Derriford Hospital, Plymouth, United Kingdom
A Phase I Trial of Anti-GD2 T-cells (1RG-CART)
- Conditions
- Relapsed or Refractory Neuroblastoma
- Interventions
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 17
- Registration Number
- NCT02761915
- Locations
- 🇬🇧
University College London Institute of Child Health & Great Ormond Street Hospital, London, United Kingdom
Phase I Study of MOv18 IgE
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 26
- Registration Number
- NCT02546921
- Locations
- 🇬🇧
Guy's and St Thomas's Hospital, London, United Kingdom
🇬🇧Addenbrooke's Hospital, Cambridge, Cambridge, United Kingdom
🇬🇧Royal Marsden Hospital, Sutton, United Kingdom
AMG 319 in HPV Positive and Negative HNSCC
- Conditions
- Human Papillomavirus (HPV)Positive or Negative Head and Neck Squamous Cell Carcinoma (HNSCC) of the Hypopharynx, Oropharynx, Oral Cavity, Supraglottis or Larynx
- Interventions
- Drug: AMG 319 hydrateDrug: Placebo
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 35
- Registration Number
- NCT02540928
- Locations
- 🇬🇧
Southampton General Hospital, Southampton, United Kingdom
🇬🇧Queen Alexandra Hospital, Department of Oral and Maxillofacial Surgery, Portsmouth, United Kingdom
🇬🇧Churchill Hospital, Blenheim H&N Unit, Oxford, United Kingdom